N
News Analysis
tickerreport.com

www.tickerreport.com ·

Positive

insider selling resmed nysermd ceo sells 1037229 62 in stock

TAX_FNCACT_CHIEF_EXECUTIVETAX_FNCACT_EXECUTIVE_OFFICERKILLTAX_DISEASE_OVERWEIGHT

All NewsRead the full story on tickerreport.com

The full article is on the original publisher site. This page only shows the headline and a very short excerpt.

AI insight

AI-generated

Insider sale by ResMed CEO under a pre-arranged trading plan; no direct commercial mechanism affecting product prices, supply chains, or margins. The sale is routine and does not signal operational change. No sector impact identified.

Signals our AI researcher identified

Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.

  • ResMed CEO Michael Farrell sold 4,991 shares on May 7, 2026 for $1,037,229.62.
  • Sale was under a pre-arranged Rule 10b5-1 trading plan.
  • ResMed quarterly revenue of $1.43 billion exceeded analyst estimates.
  • Quarterly dividend of $0.60 per share to be paid June 18, 2026.
  • CEO now owns 466,223 shares valued at ~$96.89 million.

Related stories

finance.yahoo.com

zillow zg q1 2026 earnings 225404880

finance.yahoo.com

nve nvec q4 2026 earnings 221728418

finance.yahoo.com

oncology institute q1 earnings call 050614985

finance.yahoo.com

barrett bbsi q1 2026 earnings 221818315

economictimes.indiatimes.com

zydus lifesciences shares jump 6 on buyback buzz co announces 166 mn assertio acquisition

About the publisher

tickerreport.com is one of the en-language news outlets that News Analysis aggregates. Coverage from this source appears in our global feed alongside the publisher's own reporting.

Topic context

Coverage of incidents involving fatalities. Numbers and causes are taken from primary reporting.

insider selling resmed nysermd ceo sells 1037229 62 in stock | tickerreport.com — News Analysis